ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Chemokine Receptors"

  • Abstract Number: 007 • 2020 Pediatric Rheumatology Symposium

    Dense Genotyping of Immunologic Loci Identifies CXCR4 as a Novel Susceptibility Locus for Systemic Juvenile Idiopathic Arthritis

    Emily Shuldiner 1, Elaine Remmers 2, Miranda Marion 3, Marc Sudman 4, Colleen Satorius 5, International Childhood Arthritis Genetics Consortium (INCHARGE), Juvenile Arthritis Consortium for the Immunochip (JACI), Wendy Thomson 6, Michael Ombrello1, Patricia Woo 7, Carl Langefeld 8, Sampath Prahalad 9 and Susan Thompson 10, 1NIAMS, NIH, Bethesda, 2National Human Genome Research Institute, Bethesda, 3Wake Forest University, Winston-Salem, 4Cincinnati Children's Hospital Medical Center, Cincinnati, 5NHGRI, NIH, Bethesda, 6Manchester Academic Health Science Centre, Manchester, United Kingdom, 7London, United Kingdom, 8Winston Salem, 9Emory + Children's Pediatric Institute, Atlanta, 10Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati

    Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a severe, potentially lethal inflammatory condition. It accounts for a disproportionate share of morbidity and mortality among childhood…
  • Abstract Number: 17 • 2019 ACR/ARP Annual Meeting

    Transcription Factor Fli-1 Impacts Lupus Nephritis by Orchestrating CXCL10/CXCR3 Axis

    Xuan Wang1, Mara Lennard Richard 1, Tomika Caldwell 2, Brittany Henry 2, Tammy Nowling 2, Jim Oates 3, Gary Gilkeson 4 and Xian Zhang 1, 1Medical University of South Carolina, Charleston, SC, 2Medical University of South Carolina, Charleston, 3Division of Rheumatology & Immunology/Medical University of South Carolina, Charleston, SC, 4Division of Rheumatology & Immunology/Ralph H. Johnson VA Medical Center/Medical University of South Carolina, Charleston, SC

    Background/Purpose:  Lupus nephritis is a major cause of death in both animal models and human patients.  Expression of Fli-1, a member of the Ets family…
  • Abstract Number: 21 • 2019 ACR/ARP Annual Meeting

    Immuno-Phenotypic Analysis of Peripheral Blood Mononuclear Cells in Rheumatoid Arthritis Patients Treated with E6011, a Humanized Anti-Fractalkine Monoclonal Antibody

    Tomohiro Yamada1, Jungo Kakuta 1, Eri Fusaoka-Nishioka 1, Jun-ichi Ito 2, Nobuyuki Yasuda 3, Tetsu Kawano 3 and Toshio Imai 3, 1KAN Research Institute Inc., Kobe, Japan, 2EISAI Co. Ltd., Tsukuba, Japan, 3KAN Research Institute, Inc., Kobe, Japan

    Background/Purpose: Fractalkine (FKN) and its solo receptor CX3CR1 are deeply involved in the pathogenesis of rheumatoid arthritis (RA). FKN is expressed on vascular endothelium, while…
  • Abstract Number: 103 • 2018 ACR/ARHP Annual Meeting

    Identification of IL-17+ and IL-10+ TCRαβ+ CD4- CD8- double Negative (DN) T Cell Subsets in Lupus-Prone Mice and Patients with SLE and Their Significance in Predicting Renal Involvement

    Yi Li1, Hao Li2, Vasileios C. Kyttaris3 and George C Tsokos4, 1Medicine, BIDMC, Boston, MA, 2Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 3Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, Boston, MA, 4Division of Rheumatology, Department of Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, Boston, MA

    Background/Purpose: We have previously shown that DN T cells are expanded in both lupus-prone mice and patients with SLE and we have demonstrated that this…
  • Abstract Number: 984 • 2018 ACR/ARHP Annual Meeting

    Reduced Expression of CX3CR1 in Peripheral CD14++CD16+monocytes Is a Novel Feature of Patients with Systemic Lupus Erythematosus

    Keiko Yoshimoto1, Katsuya Suzuki1, Shuntaro Saito2, Jun Kikuchi1 and Tsutomu Takeuchi1, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 2Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan

    Background/Purpose: Fractalkine (FKN, CX3CL1) and its receptor, CX3CR1, play an important role in chemotaxis of immune cells, such as cell adhesion, migration and infiltration into…
  • Abstract Number: 995 • 2018 ACR/ARHP Annual Meeting

    Anti-Fractalkine Monoclonal Antibody Inhibits Joint Destruction through Suppression of Osteoclast Precursor Migration and Induces Synovial Cell Death in Collagen-Induced Arthritis Model Mice

    Kana Hoshino-Negishi1, Masayoshi Ohkuro2, Tomoya Nakatani1, Wataru Ikeda1, Yoshikazu Kuboi1, Naoto Ishii1, Nobuyuki Yasuda1 and Toshio Imai3, 1KAN Research Institute, Inc., Kobe, Japan, 2Research Project Promotion Group, EA Pharma Co., Ltd., Kawasaki, Japan, 3President & CEO, Chief Scientific Officer, KAN Research Institute, Inc., Kobe, Japan

    Background/Purpose: In the Phase 1/2 clinical study, E6011, a novel humanized anti-fractalkine (FKN) mAb demonstrated a promising efficacy in active RA patients who were inadequately…
  • Abstract Number: 1001 • 2018 ACR/ARHP Annual Meeting

    Anti-Fractalkine Monoclonal Antibody Dislodges Intravascular Monocytes Involved in Exacerbation of Synovial Inflammation in Collagen-Induced Arthritis Model

    Wataru Ikeda1, Kana Hoshino-Negishi1, Eri Fusaoka-Nishioka1, Tomoya Nakatani1, Yoshikazu Kuboi1, Naoto Ishii1, Nobuyuki Yasuda1 and Toshio Imai2, 1KAN Research Institute, Inc., Kobe, Japan, 2President & CEO, Chief Scientific Officer, KAN Research Institute, Inc., Kobe, Japan

    Background/Purpose: In the Phase 1/2 clinical study, E6011, a novel humanized anti-fractalkine (FKN) mAb demonstrated a promising efficacy in active RA patients who were inadequately…
  • Abstract Number: 1023 • 2018 ACR/ARHP Annual Meeting

    Plasmacytoid Dendritic Cells That Infiltrate the Lungs Produce Profibrotic Cytokines and Chemokines in Bleomycin-Induced Model of Systemic Sclerosis

    Isela Valera1 and Ram R. Singh2, 1Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, UCLA, Los Angeles, CA, 2UCLA, Los Angeles, CA

    Background/Purpose: In bleomycin-induced model of systemic fibrosis and patients with systemic sclerosis, plasmacytoid DC (pDC) are unaffected or reduced systemically (spleen/peripheral blood) but they increase…
  • Abstract Number: 1914 • 2017 ACR/ARHP Annual Meeting

    Discovery of a Novel CD8+ T Cell Population in Ankylosing Spondylitis Implicates Gut-Joint Trafficking in the Disease

    Zoya Qaiyum1,2, Eric Gracey3,4, Yuchen Yao3,4 and Robert D Inman5, 1Genetics and Development, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 2Department of Immunology, University of Toronto, Toronto, ON, Canada, 3Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada, 5Immunology and Institute of Medical Science, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Ankylosing spondylitis (AS) has a strong connection with gut inflammation: 10% of AS patients have inflammatory bowel disease (IBD) and 60% have subclinical ileal…
  • Abstract Number: 2231 • 2017 ACR/ARHP Annual Meeting

    MCC22, a Novel Compound That Targets Both CCR5 and Mu Opioid Receptors, Is Highly Effective in Treating Inflammatory Arthritis Pain

    Raini Dutta1, Mary Lunzer2, Jennifer L. Auger3, Eyup Akgün2, Philip Porthoghese2 and Bryce A. Binstadt3, 1Pediatrics, University of Minnesota, Minneapolis, MN, 2Department of Medicinal Chemistry, University of Minnesota, Minneapolis, MN, 3Center for Immunology and Department of Pediatrics, University of Minnesota, Minneapolis, MN

    Background/Purpose: The pain that accompanies rheumatoid arthritis and other chronic inflammatory conditions is difficult to manage. Although opioids provide potent analgesia, chronic opioid use is…
  • Abstract Number: 2232 • 2017 ACR/ARHP Annual Meeting

    A Role for CCR2 in Chronic Behavioral and Neuroimmune Changes in the DMM Model of Osteoarthritis

    Phuong Tran1, Shingo Ishihara2, Rachel E. Miller3, Richard J. Miller4 and Anne-Marie Malfait1, 1Rheumatology, Rush University Medical Center, Chicago, IL, 2Internal Medicine, Rush University Medical Center, Chicago, IL, 3Biochemistry, Rush University Medical Center, Chicago, IL, 4Pharmacology/Medical Humanities and Bioethics, Northwestern University, Chicago, IL

    Background/Purpose: The aim of this study was to explore pain-related behaviors and associated cellular changes in the pain pathway in experimental osteoarthritis (OA) induced by…
  • Abstract Number: 40 • 2017 ACR/ARHP Annual Meeting

    B-Cell Attracting Chemokine-1 (BCA-1) and Macrophage Inflammatory Protein-3 Alpha (MIP-3α) Act Synergistically in the Recruitment of B Cells in the Rheumatoid Synovium

    Estefanía Armas-González1, María Jesús Domínguez-Luis2, María Teresa Arce-Franco3, Javier Castro-Hernández3, Vanesa Hernandez4, Sagrario Bustabad5, Alberto Cantabrana-Alutiz6 and Federico Díaz-González7, 1Universidad de La Laguna, Departamento de Medicina Física y Farmacología, Facultad de Medicina, La Laguna, Tenerife, Spain, 2Laboratorio de Reumatología. Hospital Universitario de Canarias, La Laguna, Spain, 3Laboratorio de Reumatología. Hospital Universitario de Canarias, La Laguna, Tenerife, Spain, 4Rheumatology, Servicio de Reumatología. Hospital Universitario de Canarias, S/C Tenerife, Spain, 5Rheumatology, Servicio de Reumatología. Hospital Universitario de Canarias, La Laguna, Tenerife, Spain, 6Servicio de Reumatología. Hospital Universitario Nuestra Señora de Candelaria, La Laguna, Tenerife, Spain, 7Servicio de Reumatología. Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain

    Background/Purpose: B cells are recognized as key players in the pathogenesis of rheumatoid arthritis (AR) through the production of autoantibodies, the local production of proinflammatory…
  • Abstract Number: 397 • 2017 ACR/ARHP Annual Meeting

    Anti-Fractalkine Monoclonal Antibody Ameliorates Joint Destruction in Collagen-Induced Arthritis Model through Suppression of Osteoclast Precursor Cell Survival and Migration

    Yoshikazu Kuboi1, Kana Hoshino-Negishi1, Masayoshi Ohkuro2, Wataru Ikeda1, Tomoya Nakatani1, Naoto Ishii1, Toshihiko Yamauchi1, Nobuyuki Yasuda1 and Toshio Imai3, 1KAN Research Institute, Inc., Chuo-ku, Kobe-shi, Japan, 2Research Project Promotion Group, EA Pharma Co., Ltd., Kawasaki-ku, Kawasaki-shi, Japan, 3KAN Research Institute, Inc., Kobe, Japan

    Background/Purpose: In the Phase 1/2 clinical study, E6011, a novel humanized anti-fractalkine (FKN) mAb demonstrated a promising efficacy in active RA patients who were inadequately…
  • Abstract Number: 553 • 2017 ACR/ARHP Annual Meeting

    Decreased Circulating CXCR3+CCR9+ Th Cells Coincides with Elevated Levels of Their Ligands CXCL10 and CCL25 in the Salivary Gland of Sjögren’s Syndrome Patients Which Synergistically Facilitate Th Cell Migration

    Sofie L.M. Blokland1,2, Maarten R. Hillen3,4, Stephan Meller5, Bernhard Homey5, Glennda Smithson6, Aike A. Kruize2, Timothy R.D.J. Radstake2,7 and Joel A.G. van Roon2,3, 1Rheumatology & Clinical Immunology/ Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 3Laboratory of Translational Immunology, UMC Utrecht, Utrecht, Netherlands, 4Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 5Department of Dermatology, University of Düsseldorf, Düsseldorf, Germany, 6Takeda Global Research & Development Center, Inc, Chicago, IL, 7Rheumatology and Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: Primary Sjögren’s syndrome (pSS) is characterized by dryness and lymphocytic infiltration in the salivary glands. CXCR3+ T cells and ligands CXCL9/10/11 are known to…
  • Abstract Number: 724 • 2017 ACR/ARHP Annual Meeting

    Antibodies Against the Chemokine Receptors CXCR3 and CXCR4 Predict Progressive Lung Fibrosis in Systemic Sclerosis (SSc)

    Gabriela Riemekasten1, Elise Siegert2 and Harald Heidecke3, 1Department of Rheumatology, Universitatsklinikum Schleswig-Holstein, Lubeck, Germany, 2Rheumatology and Clinical Immunology, University Hospital Charité, Berlin, Germany, 3CellTrend GmbH Luckenwalde, Luckenwalde, Germany

    Background/Purpose: Chemokine receptors CXCR3 and CXCR4 are involved in immune cell migration and in the pathogenesis of inflammatory fibrosis, a key feature of systemic sclerosis…
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology